MC0518

Phase 2Biologic

Mmedac GmbH

MC0518 is one of 39 biologic programs targeting Acute Graft Versus Host Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Graft Versus Host DiseaseActive, not recruiting

Acute Graft Versus Host DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Acute Graft Versus Host Disease

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

8 2

Entyvio

Takeda

Phase 3

1 3

Enbrel

IImmunex

Phase 3

3 4

8-Mop

TTherakos, Inc., a Mallinckrodt Company

Phase 3

2 5

Medrol

Pfizer

Phase 2

9 6

Cellcept

Roche

Phase 2

8 7

Nipent

Pfizer

Phase 2

2 8

Epidiolex

Jazz Pharmaceuticals

Phase 2

2 9

Neoral

Novartis

Phase 2

1 10

Rapamune

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Recruiting

Steroid-Refractory Acute Graft-Versus-Host Disease

NCT04629833

Q2 2031

Phase 2Active, not recruiting

Acute Graft Versus Host Disease

NCT06075706

Clinical

Trials by Indication[1]

Acute Graft Versus Host Disease1 trial

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease

Active, not recruiting·Mmedac GmbH·Phase 2·NCT06075706·48 enrolled

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting·Mmedac GmbH·Phase 3·NCT04629833·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MC0518. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MC0518 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MC0518. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — medac GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Mmedac GmbH

MC0518

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q2 2031

Trials by Indication[1]

Acute Graft Versus Host Disease1 trial

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

References

Drug Info

Quick Facts

Related News